AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Japan becomes the first country to approve Roche's personalised medicine Rozlytrek
- FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab)
- FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
- Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
- Nucala (mepolizumab) gains FDA approval for two new self-administration options
Research & Development
- Vitamin D may not help your heart
- Researchers identify enzyme that suppresses immune system in breast cancer
- Making it personal: How genetic technologies are changing the face of medicine
- Weighing risks and benefits of drug treatment for major depression
- Study finds FDA dermatology advisors receive payments following drug approvals
- Cleveland researchers test novel gene therapy for glioblastoma
- Prescription drug costs steadily soar, yet price transparency is lacking
Conferences & Events
- Ophthalmic Drugs Conference 2019
- Lyophilization USA Conference 2019
- Highly Potent Active Pharmaceutical Ingredients USA (HPAPI) Conference
- Wearable Injectors and Connected Devices Conference 2019
- Researchers block protein that plays a key role in Alzheimer's disease
- Highly Potent APIs 2019 Conference
- SMi's 9th Annual Conference: Biobanking 2019
Regulatory Affairs
- FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
- FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with cancer
- FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
- FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
- FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis